May 10, 2018
Orbis Research announces that it has released a new market research report on “Global Anti-Viral Therapeutics Market” to its database.

Dallas, United States - May 10, 2018 /MarketersMedia/ —
The global anti-viral Therapeutics market is expected to register a CAGR of 6.2% during the forecast period, 2018 to 2023. North America dominates the market due to growing prevalence of Hepatitis C & HIV infections, coupled with the presence of huge patient pool suffering from virally infectious diseases.
Request a sample of this report @ http://orbisresearch.com/contacts/request-sample/2126805 .
High Prevalence of Different Viral Infection
According to the World Health Organization (WHO), it is estimated that in 2015, nearly 36.7 million individuals had HIV. It has been identified that most of this prevalence is in low and middle-income countries. According to UNAIDS in 2016, around 1.8 million people with new HIV infection were reported worldwide. In 2017, 20.9 million people were accessing antiretroviral therapy, globally. The huge patient pool indicates high demand for anti-viral drugs, which will likely drive the market growth during the forecast period.Other factors that drive the market include increasing initiatives by public and private companies, advancements in molecular biology promoting drug development, and a strong pipeline for antiviral drugs.
Therapeutics Going Off-patent
Therapeutics losing patent exclusivity affects the market largely. Along with the innovator company, there are many regional/local players in the market. Due to this, the prices of the Therapeutics come down rapidly and the overall market gets affected. In the year 2016 itself, quite a few HIV Therapeutics had gone off-patent. Epzicom, Trizivir, Norvir, and Kaletra lost patent exclusivity in 2016. Abbott’s Kaletra has more than 8% share in the HIV anti-virals market. This will greatly affect the market for anti-viral drugs.The high cost of anti-viral drug treatment also hinders the growth of the market.
Browse the full report @ http://www.orbisresearch.com/reports/index/global-anti-viral-therapeutics-market-growth-trends-and-forecasts-2018-2023 .
North America to Dominate the Market
North America dominates the global anti-viral Therapeutics market owing to the presence of well-established market players, and growing prevalence of HIV and Hepatitis C infections. Asia-Pacific is expected to grow tremendously during the forecast period owing to factors, such as high prevalence of HIV infection, growing awareness regarding HIV infection, and increasing collaboration between public and private sectors to provide affordable treatment to the low and middle-income countries.
Key Developments in the Market
February 2018: Gilead Sciences Inc received approval from US Food and Drug Administration (FDA), for Biktarvy, a daily single tablet regimen (STR) for the treatment of HIV-1 infection.
August 2017: AbbVie received approval from US Food and Drug Administration, for MAVYRET (glecaprevir/pibrentasvir), treatment for adults with chronic hepatitis C virus (HCV) infection.
Major Players: ABBVIE, INC., BRISTOL-MEYRS SQUIBB COMPANY, CIPLA, INC., F. HOFFMANN-LA ROCHE LTD., GILEAD SCIENCES INC, GLAXOSMITHKLINE PLC, MERCK & CO., INC., PFIZER INC., SANOFI, AND JOHNSON & JOHNSON, amongst others.
Reasons to Purchase this Report
Current and future global anti-viral therapeutics market outlook in the developed and emerging markets
Analyzing various perspectives of the market with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares and strategies employed by the major market players
3 months analyst support along with the Market Estimate sheet (in excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Purchase a copy of this report @ http://orbisresearch.com/contact/purchase/2126805 .
Companies Mentioned:
ABBVIE, INC., BRISTOL-MEYRS SQUIBB COMPANY, CIPLA, INC., F. HOFFMANN-LA ROCHE LTD., GILEAD SCIENCES INC, GLAXOSMITHKLINE PLC, MERCK & CO., INC., PFIZER INC., SANOFI, AND JOHNSON & JOHNSON
Contact Info:
Name: Hector Costello
Email: [email protected]
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A.
Phone: +1 (214) 884-6817
For more information, please visit http://orbisresearch.com/
Source: MarketersMedia
Release ID: 343657
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, which gave a much rosier outlook to investors.
New tools by artificial intelligence companies like Anthropic have reignited worries that businesses will pare down their subscriptions to software services.
The N.F.L. claims Guardian Caps reduce the risk of concussions. The company that makes them says, “It has nothing to do with concussions.”
Bar owner Jobe Ferguson says he is devastated to close TNQ in the Northern Quarter after 22 years.
The company reported total revenue of $802.3 million for the fourth quarter of 2025, up 10.4 percent from a year earlier.
Please tell us what changes you’ve made to your health and wellness practices to improve your brain function and job performance. We may include your experiences in an article.
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.
The two-year-old company, founded by veterans of the autonomous vehicle business Waymo, is seeking to automate excavators and other building equipment.
Precious metal price voliatility continues as geopolitical tensions push investors to safe-haven assets.
Prized for its beauty, teak is in short supply, forcing the yacht industry to look for alternatives.
Millions could be entitled to compensation as a result of commission arrangements between lenders and dealers.
In a country roiled by political upheaval recently, retiring the longtime currency, the lev, prompted some concern about inflation but little other angst.
When President Trump said he wanted to drive housing prices up, not down, he was speaking to a conundrum that has flummoxed policymakers for decades.
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and Express Scripts that oversee prescription drug benefits.
Gold has fallen from recent highs but there are several reasons investors are still finding refuge in the precious metal.
The social media platform recently announced that it was axing around 15% of its workforce.
Experts are reaching to divine the president’s approach to global policy and economics, with one theory seeing antecedents in centuries-old dynastic rule.
Tyson Foods said its beef business could lose up to $500 million this year as the supply of cattle reaches a 75-year low.
The show on Sunday drew about 14.4 million people. It is the second consecutive year that the awards ceremony attracted a smaller audience.
Elon Musk's X and Grok platforms are facing increased scrutiny from authorities on both sides of the channel.
Mr. Miran had taken a leave of absence from advising the president after adding a role at the Federal Reserve, drawing criticism from Democrats.
Senators asked Ted Sarandos about whether the acquisition would raise prices, squeeze talent and degrade the moviegoing experience.
Concerns were raised by a subcommittee including potential price rises and the future of cinemas.
Comac's passenger jet is attracting customers in South East Asia where demand for affordable aircraft is growing.
The company’s rapid e-commerce growth and push into automation and artificial intelligence propelled its stock into the trillion-dollar club.
Little snowpack, strikes by mountain staff and Trump administration policies that are keeping international visitors away have made this a difficult season in the Rockies and beyond.
The move followed a yearlong investigation into X and escalated a wider standoff between European officials and American tech companies over the regulation of social media.
A group of cryptocurrency investors backing a memecoin hopes the statue will soon be installed at one of Mr. Trump’s golf courses in Florida.
Officials and business leaders welcomed lower tariffs, but India has not yet confirmed that it would stop buying Russian oil, which President Trump said Prime Minister Narendra Modi had agreed to.
Newly released emails between Mr. Karp, the chairman of Paul Weiss, and Jeffrey Epstein reveal a number of social interactions between them.
The media giant chooses the head of its amusement park business to replace longtime boss Bob Iger.
Jeffrey Epstein wanted most of his money to go to his girlfriend. Mr. Epstein’s brother and a Harvard math professor were also named beneficiaries.
The food and beverage giant said consumers were facing “affordability limitations.”
But a lawyer who has been scrutinizing archives and UBS are in a dispute over access to about 150 documents.
The milestone reflects the US retail giant's booming e-commerce business and investors' embrace of its AI investments.
Novel approaches to the all-day cafe are working for diners and creative chefs across the country.
The snack conglomerate is cutting the price of products including Doritos, Cheetos and Lays
Mr. D’Amaro, 54, has most recently served as chairman of Disney Experiences, a division that includes theme parks, cruise vacations and consumer products.
Ms. Tanner was previously an executive at CBS News and serves on the board of Audacy, a major U.S. broadcaster and podcast producer.
Eluned Morgan said her government can't be expected "to step in and do the work" to save struggling pubs.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.